Analysis and Commentary STEVEN GROSSMAN 10/29/21 Analysis and Commentary STEVEN GROSSMAN 10/29/21 Q&A on Implications for FDA under ARPA-H Read More Advocacy at a Glance STEVEN GROSSMAN 10/29/21 Advocacy at a Glance STEVEN GROSSMAN 10/29/21 FDA May Gain $300 Million for Infrastructure from House Reconciliation Bill; Update on Status of FY 22 FDA Appropriations Read More Advocacy at a Glance STEVEN GROSSMAN 10/22/21 Advocacy at a Glance STEVEN GROSSMAN 10/22/21 Senate Labor-HHS funding Bill has several FDA references; bipartisan House Members urges USDA and FDA to cooperate on animal genetics Read More Analysis and Commentary STEVEN GROSSMAN 10/22/21 Analysis and Commentary STEVEN GROSSMAN 10/22/21 Summary of: Alliance Webinar with National Center for Toxicological Research Director Dr. Slikker, Jr. Read More Analysis and Commentary STEVEN GROSSMAN 10/15/21 Analysis and Commentary STEVEN GROSSMAN 10/15/21 More Q&As on the Status of Appropriations and the Nomination of a New FDA Commissioner Read More Advocacy at a Glance STEVEN GROSSMAN 10/15/21 Advocacy at a Glance STEVEN GROSSMAN 10/15/21 A Funding Reprieve Via CR, but Challenges Ahead;Next Steps in the Executive Branch’s Shaping of Possible ARPA-H Read More Analysis and Commentary STEVEN GROSSMAN 10/8/21 Analysis and Commentary STEVEN GROSSMAN 10/8/21 Q&As About the upcoming appointment of a new FDA Commissioner Read More Advocacy at a Glance STEVEN GROSSMAN 10/8/21 Advocacy at a Glance STEVEN GROSSMAN 10/8/21 Temporary Truce in the Budget/Debt Limit Wars; FY 22 Appropriations Bills Still Hostage. Read More Analysis and Commentary STEVEN GROSSMAN 10/1/21 Analysis and Commentary STEVEN GROSSMAN 10/1/21 Q&As on FDA Allocations: BA vs user fees; medical products vs food safety Read More Advocacy at a Glance STEVEN GROSSMAN 10/1/21 Advocacy at a Glance STEVEN GROSSMAN 10/1/21 Continuing Resolution prevent shutdown, but delays decisions; ARPA-H is a work in progress Read More Analysis and Commentary STEVEN GROSSMAN 9/24/21 Analysis and Commentary STEVEN GROSSMAN 9/24/21 Consequences of an FDA shutdown at the beginning of FY 22 Read More Advocacy at a Glance STEVEN GROSSMAN 9/24/21 Advocacy at a Glance STEVEN GROSSMAN 9/24/21 Shutdown possible; Updates on food safety and OTC monographs Read More Analysis and Commentary STEVEN GROSSMAN 9/17/21 Analysis and Commentary STEVEN GROSSMAN 9/17/21 Q&A on what happens if a CR isn’t passed; FDA’s role is ARPA-H is created Read More Advocacy at a Glance STEVEN GROSSMAN 9/17/21 Advocacy at a Glance STEVEN GROSSMAN 9/17/21 FY 22 Continuing Resolution (CR) up next; best scenario for FDA; FDA aided by Reconciliation if it passes Read More Analysis and Commentary STEVEN GROSSMAN 9/10/21 Analysis and Commentary STEVEN GROSSMAN 9/10/21 Clarifying some issues about FDA budget and appropriations. Read More Advocacy at a Glance STEVEN GROSSMAN 9/10/21 Advocacy at a Glance STEVEN GROSSMAN 9/10/21 Potential for a long endgame on appropriations; A government shutdown is highly unlikely, but not unimaginable. Read More Analysis and Commentary STEVEN GROSSMAN 9/3/21 Analysis and Commentary STEVEN GROSSMAN 9/3/21 The difference between micro- and macro-budgetary issues and how they affect FDA Read More Advocacy at a Glance STEVEN GROSSMAN 9/3/21 Advocacy at a Glance STEVEN GROSSMAN 9/3/21 House/Senate Appropriations have finished Ag/FDA funding, long end game lies ahead; FDA Rulemaking Authority restored, Sunset Rule delayed Read More Advocacy at a Glance Lisa Ellington 8/27/21 Advocacy at a Glance Lisa Ellington 8/27/21 Items for when Congress returns in late August Read More Advocacy at a Glance Lisa Ellington 8/20/21 Advocacy at a Glance Lisa Ellington 8/20/21 Items for when Congress returns in late August Read More Newer Posts Older Posts
Analysis and Commentary STEVEN GROSSMAN 10/29/21 Analysis and Commentary STEVEN GROSSMAN 10/29/21 Q&A on Implications for FDA under ARPA-H Read More
Advocacy at a Glance STEVEN GROSSMAN 10/29/21 Advocacy at a Glance STEVEN GROSSMAN 10/29/21 FDA May Gain $300 Million for Infrastructure from House Reconciliation Bill; Update on Status of FY 22 FDA Appropriations Read More
Advocacy at a Glance STEVEN GROSSMAN 10/22/21 Advocacy at a Glance STEVEN GROSSMAN 10/22/21 Senate Labor-HHS funding Bill has several FDA references; bipartisan House Members urges USDA and FDA to cooperate on animal genetics Read More
Analysis and Commentary STEVEN GROSSMAN 10/22/21 Analysis and Commentary STEVEN GROSSMAN 10/22/21 Summary of: Alliance Webinar with National Center for Toxicological Research Director Dr. Slikker, Jr. Read More
Analysis and Commentary STEVEN GROSSMAN 10/15/21 Analysis and Commentary STEVEN GROSSMAN 10/15/21 More Q&As on the Status of Appropriations and the Nomination of a New FDA Commissioner Read More
Advocacy at a Glance STEVEN GROSSMAN 10/15/21 Advocacy at a Glance STEVEN GROSSMAN 10/15/21 A Funding Reprieve Via CR, but Challenges Ahead;Next Steps in the Executive Branch’s Shaping of Possible ARPA-H Read More
Analysis and Commentary STEVEN GROSSMAN 10/8/21 Analysis and Commentary STEVEN GROSSMAN 10/8/21 Q&As About the upcoming appointment of a new FDA Commissioner Read More
Advocacy at a Glance STEVEN GROSSMAN 10/8/21 Advocacy at a Glance STEVEN GROSSMAN 10/8/21 Temporary Truce in the Budget/Debt Limit Wars; FY 22 Appropriations Bills Still Hostage. Read More
Analysis and Commentary STEVEN GROSSMAN 10/1/21 Analysis and Commentary STEVEN GROSSMAN 10/1/21 Q&As on FDA Allocations: BA vs user fees; medical products vs food safety Read More
Advocacy at a Glance STEVEN GROSSMAN 10/1/21 Advocacy at a Glance STEVEN GROSSMAN 10/1/21 Continuing Resolution prevent shutdown, but delays decisions; ARPA-H is a work in progress Read More
Analysis and Commentary STEVEN GROSSMAN 9/24/21 Analysis and Commentary STEVEN GROSSMAN 9/24/21 Consequences of an FDA shutdown at the beginning of FY 22 Read More
Advocacy at a Glance STEVEN GROSSMAN 9/24/21 Advocacy at a Glance STEVEN GROSSMAN 9/24/21 Shutdown possible; Updates on food safety and OTC monographs Read More
Analysis and Commentary STEVEN GROSSMAN 9/17/21 Analysis and Commentary STEVEN GROSSMAN 9/17/21 Q&A on what happens if a CR isn’t passed; FDA’s role is ARPA-H is created Read More
Advocacy at a Glance STEVEN GROSSMAN 9/17/21 Advocacy at a Glance STEVEN GROSSMAN 9/17/21 FY 22 Continuing Resolution (CR) up next; best scenario for FDA; FDA aided by Reconciliation if it passes Read More
Analysis and Commentary STEVEN GROSSMAN 9/10/21 Analysis and Commentary STEVEN GROSSMAN 9/10/21 Clarifying some issues about FDA budget and appropriations. Read More
Advocacy at a Glance STEVEN GROSSMAN 9/10/21 Advocacy at a Glance STEVEN GROSSMAN 9/10/21 Potential for a long endgame on appropriations; A government shutdown is highly unlikely, but not unimaginable. Read More
Analysis and Commentary STEVEN GROSSMAN 9/3/21 Analysis and Commentary STEVEN GROSSMAN 9/3/21 The difference between micro- and macro-budgetary issues and how they affect FDA Read More
Advocacy at a Glance STEVEN GROSSMAN 9/3/21 Advocacy at a Glance STEVEN GROSSMAN 9/3/21 House/Senate Appropriations have finished Ag/FDA funding, long end game lies ahead; FDA Rulemaking Authority restored, Sunset Rule delayed Read More
Advocacy at a Glance Lisa Ellington 8/27/21 Advocacy at a Glance Lisa Ellington 8/27/21 Items for when Congress returns in late August Read More
Advocacy at a Glance Lisa Ellington 8/20/21 Advocacy at a Glance Lisa Ellington 8/20/21 Items for when Congress returns in late August Read More
